The Boston-based biotech is having a ball after signing a deal with Novartis to the tune of $150 million for a molecular glue degrader, developed using the company’s QuEEN platform, that makes ...

Novartis will apply Monte Rosa Therapeutics’ target discovery platform to develop its T and B cell-modulating molecular glue degraders targeting the VAV1 protein—starting with its Phase I ...

The HBO host clumped Donald Trump with a selection of history’s most hated dictators, and Kelly was quick to retaliate against the democrats. Reporter Adolf Hitler comparisons were rife during ...